Oaktree Acquisition Corp. III Life Sciences (OACC)
OACC 8-K filings in 2025
Every material Form 8-K Oaktree Acquisition Corp. III Life Sciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chief Financial Officer Thomas Sweeney resigned effective October 29, 2025, to pursue other professional opportunities, according to the filing, and the filing states the resignation was not due to any disagreement with the board or management. The board appointed George A. Martinez, a Senior Vice President in Oaktree's finance organization, as CFO effective immediately, and he will not receive compensation from the company for the role.
Thomas Sweeney resigned as Chief Financial Officer effective October 29, 2025, citing other professional opportunities
George A. Martinez appointed Chief Financial Officer and principal accounting and financial officer effective October 29, 2025
Martinez previously was an Audit Senior Manager at Ernst & Young from 2013 to 2024 and joined Oaktree in 2024
Martinez will not be compensated by the company for the CFO role and has no employment agreement with it
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Oaktree Acquisition Corp. III Life Sciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →